Source comparison
Tesamorelin + Ipamorelin Blend Safe: Comparison
Tesamorelin (monotherapy) GHRH analog. Stimulates anterior pituitary GH release Phase III RCTs (EGRIFTA trials, n=800+) in HIV lipodystrophy Injection-site reactions (35%), arthralgia (13%), peripheral edema (7%) 5.8% due to adverse events over 26 weeks Well-c
This comparison does not assign a generated winner or score.
- Tesamorelin (monotherapy)
- GHRH analog. Stimulates anterior pituitary GH release
- Phase III RCTs (EGRIFTA trials, n=800+) in HIV lipodystrophy
- Injection-site reactions (35%), arthralgia (13%), peripheral edema (7%)
- 5.8% due to adverse events over 26 weeks
- Well-characterized safety profile in a specific population; glucose monitoring essential
- Ipamorelin (monotherapy)
- Ghrelin receptor agonist. Selective GH secretagogue
- Phase II trials (n=120–200) in postoperative recovery and age-related GH deficiency
- Injection-site discomfort (6%), transient headache (4%), mild nausea (2%)
- <3% across studies. No serious AEs reported
- Minimal HPA axis impact; favorable tolerability but limited long-term data
- Tesamorelin + Ipamorelin (combination)
- Dual pathway GH stimulation. GHRH + ghrelin receptor
- No published Phase II or III combination trials available
- Theoretically additive: injection-site reactions, joint pain, fluid retention, hyperglycemia risk
- Unknown. No controlled trial data
- Safety extrapolated from monotherapy data; requires medical oversight and glucose/IGF-1 monitoring